Strides Arcolab Limited has received approval from the United States Food & Drug Administration (FDA) for lamivudine and zidovudine tablets USP, 150 mg/300 mg.
According to IMS data, the US market for lamivudine and zidovudine tablets is approximately USD 120 million.
The product will be manufactured at the company’s oral dosage facility at Bengaluru. The product will be launched in the US markets immediately.
Lamivudine and zidovudine 150 mg/300 mg (generic version of Viiv’s Combivir) belong to a group of antiviral medicines, also known as antiretrovirals and is used with other antiretroviral medicines to treat HIV infection in adults and children. Lamivudine and zidovudine 150 mg/300 mg tablets reduces the amount of HIV in your body, and keeps it at a low level.
